https://doi.org/10.4081/hmr.v3i1.546

Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma

Vol. 3 No. 1: 2006...2009: Now we know T-cell lymphomas better, Bologna, Italy, 16-18 March 2009
Published: June 11, 2009
Abstract Views: 285
PDF: 532
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

C Querfeld
support@pagepress.org
TM Kuzel
J Guitart
ST Rosen
Thalidomide and its analogue lenalidomide Lenalidomide [3-(4’aminoisoindolin- 1’-one)-1-piperidine-2, 6- dione, Revlimid®] is the lead compound in a new class of agents which are known as the immunomodulatory drugs.1 Lenali-domide has a similar chemical structure to thalidomide. Both drugs have a comparable in vitro profile; however, lenalidomide is more potent. The US Food and Drug Administration (FDA) has approved lenalidomide for the treatment of patients with transfusion dependent anemia due to low- or intermediate- 1-risk myelodysplastic syndromes (MDS) associated with the deletion of 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.2 In addition, it is FDA approved for the treatment of patients with multiple myeloma who have failed at least one prior therapy.3 Due to its structural similarities to thalidomide, a known human teratogen, lenalidomide is approved for marketing only under a special restricted distribution program called RevAssistsm.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Querfeld, C., Kuzel, T., Guitart, J., & Rosen, S. (2009). Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma. Hematology Meeting Reports (formerly Haematologica Reports), 3(1). https://doi.org/10.4081/hmr.v3i1.546
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).